跳到正文
原文
Eric Topol· @EricTopol · X·· 3 天前AI 评分42
AI 导读

体位性心动过速综合征(POTS)目前仍无获批或高效的治疗方案,该病可致人衰弱。 如今有了希望:一项 Phase 2 随机试验结果非常令人鼓舞——一种针对利钠肽受体 1(NRP-1)的抗体 https://firstwordpharma.com/story/8433501

正文

There still in no approved or highly effective treatment for postural orthostatic tachycardia syndrome (POTS), which can be debilitating.
Now there's hope with very encouraging results of a Phase 2 randomized trial: an antibody vs natriuretic peptide receptor 1 (NRP-1)
https://firstwordpharma.com/story/8433501

来源:Eric Topol · x.com